专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3209691B1 COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES 有权转让
公开(公告)号：EP3209691B1
公开(公告)日：2020-07-15
申请号：EP15794641.9
申请日：2015-10-21
申请人： OSE Immunotherapeutics
发明人： POIRIER, Nicolas , VANHOVE, Bernard
IPC分类号： C07K16/28 , A61K39/00

2. 发明公开

EP3529262A1 METHODS FOR PROMOTING T CELLS RESPONSE 有权转让
公开(公告)号：EP3529262A1
公开(公告)日：2019-08-28
申请号：EP17797066.2
申请日：2017-10-20
申请人： INSERM - Institut National de la Santé et de la Recherche Médicale , Universite de Nantes , OSE Immunotherapeutics
发明人： CHIFFOLEAU, Elise , TEPPAZ, Géraldine , POIRIER, Nicolas , VANHOVE, Bernard , GAUTTIER, Vanessa
IPC分类号： C07K14/47

3. 发明公开

EP3209691A1 METHOD AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES 有权转让
标题翻译：诱导分化成髓样抑制细胞治疗癌症和感染性疾病的方法和组合物
公开(公告)号：EP3209691A1
公开(公告)日：2017-08-30
申请号：EP15794641.9
申请日：2015-10-21
申请人： OSE Immunotherapeutics
发明人： POIRIER, Nicolas , VANHOVE, Bernard
IPC分类号： C07K16/28 , A61K39/00
摘要： The present invention pertains to the field of immunotherapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (MDSC) into non suppressive cells, by administering a compound blocking the interaction between SIRPa and CD47 to a patient in need thereof, in order to reduce MDSC-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation.
摘要翻译：本发明涉及免疫治疗领域。更具体地说，本发明提供了一种将骨髓来源的抑制细胞（MDSC）分化成非抑制性细胞的方法，其通过向需要的患者施用阻断SIRPa和CD47之间相互作用的化合物，以降低MDSC诱导的免疫抑制并因此在癌症，感染性疾病，疫苗接种，创伤，自身免疫性疾病，慢性炎性疾病和移植中允许适当的免疫应答。

4. 发明公开

EP3783027A1 METHOD AND COMPOSITIONS FOR INDUCING DIFFERENTIATION OF MYELOID DERIVED SUPPRESSOR CELL TO TREAT CANCER AND INFECTIOUS DISEASES 审中-实审
公开(公告)号：EP3783027A1
公开(公告)日：2021-02-24
申请号：EP20177260.5
申请日：2015-10-21
申请人： OSE Immunotherapeutics
发明人： POIRIER, Nicolas , VANHOVE, Bernard
IPC分类号： C07K16/28 , A61P17/02 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/04 , A61P37/04 , A61P37/06 , A61P43/00 , A61K39/00
摘要： The present invention pertains to the field of immunotherapy. More specifically, the present invention provides a method for treating a patient having a cancer by administering a compound blocking the interaction between SIRPa and CD47. The administration of the compound blocking the interaction between SIRPa and CD47, reduces the MDSC-induced immunodepression and consequently allow appropriate immune responses in cancers.

6. 发明公开

EP3551664A1 ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127 有权转让
公开(公告)号：EP3551664A1
公开(公告)日：2019-10-16
申请号：EP17835592.1
申请日：2017-12-07
申请人： OSE Immunotherapeutics
发明人： POIRIER, Nicolas , MARY, Caroline , VANHOVE, Bernard , THEPENIER, Virginie
IPC分类号： C07K16/28 , A61P37/00

7. 发明公开

EP3390450A1 ANTI-CD28 HUMANIZED ANTIBODIES FORMULATED FOR ADMINISTRATION TO HUMANS 有权转让
公开(公告)号：EP3390450A1
公开(公告)日：2018-10-24
申请号：EP16822423.6
申请日：2016-12-15
申请人： OSE Immunotherapeutics
发明人： VANHOVE, Bernard
IPC分类号： C07K16/28 , A61P37/06
CPC分类号： C07K16/2818 , A61K9/0014 , A61K9/0019 , A61K38/47 , A61K39/3955 , A61K47/60 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P37/06 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12Y302/01035
摘要： The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.

8. 发明公开

EP3299392A1 ANTIBODIES DIRECTED AGAINST THE ALPHA CHAIN OF IL7 RECEPTOR - THEIR USE FOR THE PREPARATION OF DRUG CANDIDATES 有权
标题翻译：针对IL7受体的ALP链的抗体 - 它们用于制备候选药物的用途
公开(公告)号：EP3299392A1
公开(公告)日：2018-03-28
申请号：EP17200006.9
申请日：2012-10-04
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , OSE Immunotherapeutics
发明人： BROUARD, Sophie , MAI, Le Hoa , MARY, Caroline , POIRIER, Nicolas , SOULILLOU, Jean-Paul , VANHOVE, Bernard
IPC分类号： C07K16/28 , A61K39/395 , A61P37/06 , A61K45/06 , C07K16/24 , A61K39/00 , A61K47/60
摘要： The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7Ralpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells.
The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
摘要翻译：本发明涉及针对CD127的抗体，即，白细胞介素7受体（IL-7）的α链，特别是在人细胞（称为人IL-7Rα或IL-7Rα）或TSLP受体上表达的人IL-7受体。本发明的抗体对CD127阳性细胞具有细胞毒活性。本发明还涉及这些抗体的用途，以便通过ADCC和任选通过CDC消除由于抗体的细胞毒性作用而导致的T淋巴细胞亚群。因此，本发明涉及抗体在这些病理与CD127阳性细胞相关时用于治疗移植排斥，自身免疫性疾病，变应性疾病，淋巴瘤或癌症的用途。

9. 发明公开

EP3155014A1 ANTIBODIES DIRECTED AGAINST CD127 审中-实审
标题翻译： GEGEN CD127 GERICHTETEANTIKÖRPER
公开(公告)号：EP3155014A1
公开(公告)日：2017-04-19
申请号：EP15727989.4
申请日：2015-06-10
申请人： OSE Immunotherapeutics
发明人： POIRIER, Nicolas , MARY, Caroline , VANHOVE, Bernard
IPC分类号： C07K16/28 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/5041 , G01N33/6854 , G01N2333/5418 , G01N2333/70546 , G01N2333/7155 , G01N2500/00
摘要： The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and whichi have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising the human CD127 sequences of SEQ ID No: 110 and/or SEQ ID No: 111. The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.
摘要翻译：本发明涉及针对CD127，白细胞介素7（IL-7）受体IL-7R的α链）及其具有IL-7-IL-7R相互作用的拮抗剂性质的抗体可能对CD127阳性细胞具有细胞毒活性但不会增加由TSLP诱导的树突状细胞（DC）的成熟，细胞因子也使用CD127作为其受体的一部分。或者或另外，这些抗体不诱导CD127的内化和/或抑制IL7诱导的CD127内化。根据本发明的另一方面，提供了抗体，其识别包含SEQ ID No：110和/或SEQ ID No：111的人CD127序列的人CD127表位。本发明的抗体适用于补救特别是当IL-7信号通路对所述发病机制作出贡献时，特别是当树突状细胞的共刺激分子的上调增加是不期望的时，特别是当增加成熟度时，由患有淋巴细胞生成的发病机制导致的人类患者诊断出的症状。

10. 发明公开

EP3868785A1 ANTI-CD28 HUMANIZED ANTIBODIES FORMULATED FOR ADMINISTRATION TO HUMANS 审中-实审
公开(公告)号：EP3868785A1
公开(公告)日：2021-08-25
申请号：EP21150940.1
申请日：2016-12-15
申请人： OSE Immunotherapeutics
发明人： VANHOVE, Bernard
IPC分类号： C07K16/28 , A61P37/06
摘要： The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab' antibody fragment, called "FR104". This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式